LONDON, December 13 /PRNewswire/ --

- Your Chance to Hear and Question Sir Ranulph Fiennes on His Living Dangerously Lecture and Learn About the Plight of the Endangered African Lion

LONDON, December 13 /PRNewswire/ --

On Friday 18th January 2008 "An Audience with Sir Ranulph Fiennes and ALERT" will provide people with an exclusive opportunity to hear and question Sir Ranulph Fiennes on his worldwide adventures and endurance feats. As well as discussing quests such as being the first man to visit both the north and south poles by land, Fiennes will also be discussing his work as patron to the African Lion & Environmental Research Trust, ALERT.

An international team of scientists have sequenced the genome for Physcomitrella – the first non-flowering or ‘lower’ plant to be sequenced – and published their findings in the latest issue of Science.

The moss Physcomitrella patens is a primitive plant, similar to the first plants which began to grow on land around 450 million years ago. Just one cell thick, these early plants had to adapt to withstand cold, heat and drought without roots or complex leaves. The ability of mosses to survive severe dehydration and then regrow when watered could be of enormous use in crops grown in drought-stricken areas of the developing world.

BAAR, Switzerland, December 13 /PRNewswire/ --

- Manas Petroleum Corp. (MNAP.OB) (Manas)

"The Albanian Council of Ministers has approved Decision No. 796 regarding the approval of production sharing for exploration, development and production of hydrocarbons on onshore Albania, in Blocks A-B and D-E, between the Ministry of Economy, Trade and Energy, represented by the National Agency of Natural Resources (AKBN) and DWM Petroleum AG." DWM Petroleum AG is 100% subsidiary of Manas.

COPENHAGEN, Denmark, December 13 /PRNewswire/ --

- Summary: Genmab has Initiated a Phase II Study of Ofatumumab in Relapsed Diffuse Large B-Cell Lymphoma

Genmab A/S (OMX: GEN) announced today that study centers have been initiated and are ready to enroll patients in a Phase II study of ofatumumab (HuMax-CD20(R)) to evaluate treatment of relapsed Diffuse Large B-Cell Lymphoma (DLBCL) in patients ineligible for or relapsed following a stem cell transplant. Approximately 75 patients will be enrolled in the study which is being conducted under Genmab's collaboration with GlaxoSmithKline (GSK). Genmab will receive a milestone payment of approximately DKK 87.2 million from GSK upon treatment of the first patient in the study, expected in the near future.

PLYMOUTH, England, December 13 /PRNewswire/ --

- How do you Know if you Need to Call the Vet?

- Is it Urgent?

- Can it Wait Until a Normal Working Day?

Vet Help Direct is a free, interactive, online guide to help dog, horse, cat and rabbit owners decide if they need to contact the vet, and if so, how urgently. The website helps to alleviate the 'Can it wait until the next normal working day?' dilemma when faced with an ill or injured animal at night or on a bank holiday. The site is designed and run by British vets and is the first of its kind anywhere on the internet.

COPENHAGEN, Denmark, December 13 /PRNewswire/ --

- Summary: Genmab has Announced Details of a Planned Phase II Study of Ofatumumab to Treat Relapsing Remitting Multiple Sclerosis

Genmab A/S (OMX: GEN) announced today details of a planned Phase II study of ofatumumab (HuMax-CD20(R)) for the treatment of relapsing remitting multiple sclerosis (RRMS). Approximately 324 patients will be enrolled in the study which will be conducted under Genmab's collaboration with GlaxoSmithKline (GSK). The study is expected to begin in the first quarter of 2008.

SAN FRANCISCO, December 13 /PRNewswire/ --

- Italy's leading pay-TV operator renews agreement for OpenTV solutions

OpenTV Corp. (Nasdaq: OPTV), a leading provider of solutions for the delivery of advanced television and cross-platform interactive services, announced today that Sky Italia has entered into a multi-year renewal of its middleware license agreement with OpenTV. Sky Italia is Italy's premier provider of satellite television, offering a variety of programming choices to more than four million subscribers.

REHOVOT, Israel and NEW YORK, December 13 /PRNewswire/ --

- Target Diseases for This Collaboration are Diffuse Large Cell Lymphoma, Transformed Follicular Lymphoma, and Chronic Lymphocytic Leukemia

- Collaboration to Develop MicroRNA-Based Diagnostics Test, Early Detection and Prognosis.

- 43,000 People Will be Diagnosed With These Types of Cancers in 2007 in the US Alone(1)

- MicroRNAs Hold Significant Potential as Highly Sensitive and Specific Biomarkers for Hematological Cancers

- Collaboration Also Will Seek to Identify MicroRNA (miRNA) Targets for Therapeutic Applications

LONDON, December 13 /PRNewswire/ --

Marian Salzman, the world's no. 1 Trendspotter and Chief Marketing Officer at JWT Worldwide, is back for the third year along with Ann Mack, Director of Trendspotting at JWT, with their fascinating annual forecasts for 2008. Marian has previously brought us the metrosexual man, domestic divas, globesity, fortification and wiggers (white kids who want to be black).

Trends covered include Health, Travel, Home, Technology, Fashion and Beauty. (For more detailed information on the trends below and information on many others please see contact details below.)

Researchers at Low Temperature Laboratory and Laboratory of Physics (TKK) and at University of Stony Brook (New York) have potentially solved the problem of accurately defining the ampere. The group has developed a frequency to current converter, the accuracy of which is based on the known charge of an electron and the extreme accuracy in defining frequency. The nanodevice is essentially a single electron transistor which works as a simple single-electron turnstile. Its best performance is achieved at very low temperatures.

Previously, the electric current and its unit, the ampere, have been defined through the classical force induced to two parallel leads carrying the current.